ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: FR-PO933

Monoclonal Gammopathy of Undetermined Significance (MGUS) and Risk of CKD: Results of the Population-Based Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study

Session Information

Category: CKD (Non-Dialysis)

  • 2201 CKD (Non-Dialysis): Epidemiology‚ Risk Factors‚ and Prevention


  • Long, Thorir E., Skanes universitetssjukhus Lund, Lund, Sweden
  • Indridason, Olafur S., Landspitali, Reykjavik, Capital, Iceland
  • Rögnvaldsson, Sæmundur, University of Iceland, Reykjavík, Iceland
  • Eythorsson, Elias, Landspitali, Reykjavik, Iceland
  • Thorsteinsdóttir, Sigrún, Rigshospitalet, Kobenhavn, Denmark
  • Love, Thorvardur Jon, Heilbrigdisvisindasvid - Haskoli Island, Reykjavik, Iceland
  • Palsson, Runolfur, Landspitali, Reykjavik, Iceland
  • Kristinsson, Sigurdur Y, Heilbrigdisvisindasvid - Haskoli Island, Reykjavik, Iceland

Group or Team Name

  • iStopMM research group

The prevalence of both monoclonal gammopathies of undetermined significance (MGUS) and chronic kidney disease (CKD) increase with age. In recent years, studies have shown association between MGUS and CKD, suggesting an underdiagnosis of monoclonal gammopathies of renal significance (MGRS). The aim of this study was to examine the risk of CKD in participants with MGUS compared with those without MGUS for the first time in a screened cohort, to estimate the prevalence of MGRS.


A total of 75,422 participants of the iStopMM study were screened for MGUS. CKD was defined as proteinuria, hematuria or estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2, present for >90 days. Participants with lymphoproliferative disorders or without data on kidney function were excluded. Risk of CKD was evaluated with multivariable logistic regression. Power analysis yielded 90% power to detect 1.5% absolute difference between groups.


Of the participants, 35,202 had available urine measurements and 69,120 data on eGFR, median (range) age was 61 (52-70) years, 44.8% were men. MGUS was detected in 4547 (6.6%) participants, 2242 (3.2%) of which were non-IgM, 703 (1.0%) IgM, 1295 (1.9%) LC-MGUS, and 307 (0.4%) biclonal. A total of 6680 (9.7%) participants had CKD, 14.8% in the MGUS group and 9.3% in the group without MGUS. In an age- and sex-adjusted analysis, there was no significant association between non-IgM MGUS, IgM MGUS, or biclonal MGUS and CKD (Table I). Participants with LC-MGUS were less likely to have CKD than those without MGUS. The inverse correlation between age and eGFR was similar in the groups with and without MGUS (r= -0.56).


In this large population-based screening study, we observed no increase in the risk of CKD in individuals with MGUS. This finding suggests a low prevalence of MGRS in the general population.


  • Private Foundation Support